Ohcanbohtosat - Adi Diab
- Čájehuvvo 1 - 20 / 82
- Sirdás čuovvovaš siidui
-
1
-
2
The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes Dahkki Hamzah Abu‐Sbeih, Tenglong Tang, Faisal S. Ali, Daniel H. Johnson, Wei Qiao, Adi Diab, Yinghong Wang
Almmustuhtton 2018Artigo -
3
-
4
-
5
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson Dahkki Yinghong Wang, Hamzah Abu‐Sbeih, Emily Mao, Noman Ali, Faisal S. Ali, Wei Qiao, Phillip Lum, Gottumukkala S. Raju, Gladis Shuttlesworth, John Stroehlein, Adi Diab
Almmustuhtton 2018Revisão -
6
-
7
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy Dahkki Daniel H. Johnson, Anisha B. Patel, Marc Uemura, Van Anh Trinh, Natalie Jackson, Chrystia M. Zobniw, Michael T. Tetzlaff, Patrick Hwu, Jonathan L. Curry, Adi Diab
Almmustuhtton 2019Artigo -
8
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series Dahkki K. Holbrook, Jose Lutzky, Michael A. Davies, Jessica Davis, Isabella C. Glitza, Rodabe N. Amaria, Adi Diab, Sapna P. Patel, Asim Amin, Hussein A. Tawbi
Almmustuhtton 2019Artigo -
9
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case... Dahkki Marc Uemura, Van Anh Trinh, Cara Haymaker, Natalie Jackson, Dae Won Kim, James P. Allison, Padmanee Sharma, Luis M. Vence, Chantale Bernatchez, Patrick Hwu, Adi Diab
Almmustuhtton 2016Artigo -
10
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors Dahkki Noha Abdel‐Wahab, Adi Diab, Robert Yu, P. Andrew Futreal, Lindsey A. Criswell, Jean Tayar, Ramona Dadu, Vickie R. Shannon, Sanjay Shete, María E. Suärez-Almazor
Almmustuhtton 2021Artigo -
11
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 Dahkki Marc Uemura, Faisal Faˈak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff, Adi Diab
Almmustuhtton 2016Artigo -
12
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis Dahkki Maen Abdelrahim, Omar Mamlouk, Heather Lin, Jamie S. Lin, Valda D. Page, Noha Abdel‐Wahab, Joshua T. Swan, Umut Selamet, Cassian Yee, Adi Diab, Wadi N. Suki, Ala Abudayyeh
Almmustuhtton 2021Artigo -
13
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View Dahkki Maen Abdelrahim, Abdullah Esmail, Ashish Saharia, Ala Abudayyeh, Noha Abdel‐Wahab, Adi Diab, Naoka Murakami, Ahmed O. Kaseb, Jenny C. Chang, A. Osama Gaber, Rafik M. Ghobrial
Almmustuhtton 2022Revisão -
14
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study Dahkki Meredith Pelster, Stephen K. Gruschkus, Roland L. Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, Maura S. Glover, Rinata Simien, Adi Diab, Patrick Hwu, Brett W. Carter, Sapna P. Patel
Almmustuhtton 2020Artigo -
15
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition Dahkki Jianda Yuan, Anuradha Khilnani, Joshua Brody, Robert H.I. Andtbacka, Siwen Hu‐Lieskovan, Jason J. Luke, Adi Diab, Aurélien Marabelle, Alexandra Snyder, Z. Alexander Cao, F. Stephen Hodi
Almmustuhtton 2021Revisão -
16
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients Dahkki Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg Staerkel, Priyadharsini Nagarajan, Carlos A. Torres‐Cabala, Beth Chasen, Jennifer A. Wargo, Víctor G. Prieto, Rodabe N. Amaria, Jonathan L. Curry
Almmustuhtton 2018Artigo -
17
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity Dahkki Adam D. Cohen, Adi Diab, Miguel‐Angel Perales, Jedd D. Wolchok, Gabrielle Rizzuto, Taha Merghoub, Deonka Huggins, Cailian Liu, Mary Jo Turk, Nicholas P. Restifo, Shimon Sakaguchi, Alan N. Houghton
Almmustuhtton 2006Artigo -
18
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis Dahkki Jamie S. Lin, Omar Mamlouk, Umut Selamet, Amanda Tchakarov, William F. Glass, Rahul A. Sheth, Rachel M. Layman, Ramona Dadu, Noha Abdel‐Wahab, Maen Abdelrahim, Adi Diab, Cassian Yee, Ala Abudayyeh
Almmustuhtton 2021Artigo -
19
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation Dahkki Adam D. Cohen, David Schaer, Cailian Liu, Yanyun Li, Daniel Hirschhorn-Cymmerman, Soo Chong Kim, Adi Diab, Gabrielle Rizzuto, Fei Duan, Miguel‐Angel Perales, Taha Merghoub, Alan N. Houghton, Jedd D. Wolchok
Almmustuhtton 2010Artigo -
20
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature Dahkki Noha Abdel‐Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, María E. Suärez-Almazor, Adi Diab
Almmustuhtton 2019Revisão
Ohcanreaiddut:
Laktáseaddji fáttát
Medicine
Internal medicine
Immunotherapy
Cancer research
Immunology
Oncology
Cancer
Immune system
Melanoma
Biology
Adverse effect
Immune checkpoint
Ipilimumab
T cell
Receptor
Gastroenterology
Nivolumab
Blockade
CD8
Surgery
Clinical trial
Disease
Biochemistry
Cytotoxic T cell
Genetics
In vitro
Breast cancer
Antigen
Cancer immunotherapy
Metastatic melanoma